Becker B, Shin D H
Arch Ophthalmol. 1976 Dec;94(12):2057-8. doi: 10.1001/archopht.1976.03910040717001.
Eighty patients with ocular hypertension (intraocular pressure greater than 20 mm Hg) and GG-response to topical corticosteroids (over 31 mm Hg after six weeks of topical dexamethasome 0.1% four times a day) were tested for ocular hypotensive response to topical epinephrine. Of 80 patients observed for five to ten years, 20 (25%) developed gluacomatous visual field defects, and 34 (43%) were "responders" to topical epinephrine (IOP reduction of greater than 5 mm Hg). Of 20 patients who developed glaucomatous visual field defects, 17 (85%) had responded to topical epinephrine, but only 28% of those who did not have visual field defects showed this type of epinephrine response. Of 34 epinephrine responders, 17 (50%) developed glaucomatous visual field defects as compared to three of 46 (6.5%) nonresponders. The initial applanation IOP level proved less valuable as a prognostic indicator.
对80例眼压过高（眼压大于20毫米汞柱）且对局部皮质类固醇呈GG反应（每天4次使用0.1%地塞米松局部用药6周后眼压超过31毫米汞柱）的患者进行了局部肾上腺素的降眼压反应测试。在观察了5至10年的80例患者中，20例（25%）出现了青光眼性视野缺损，34例（43%）对局部肾上腺素“有反应”（眼压降低超过5毫米汞柱）。在20例出现青光眼性视野缺损的患者中，17例（85%）对局部肾上腺素有反应，但在没有视野缺损的患者中，只有28%表现出这种肾上腺素反应。在34例肾上腺素反应者中，17例（50%）出现了青光眼性视野缺损，而在46例无反应者中有3例（6.5%）出现了这种情况。最初的压平眼压水平作为预后指标的价值较小。
